HTA Monthly Wrap - September 2021
September 29, 2021

HTA Monthly Wrap - September 2021

Your Journey

As we move into the final quarter of another roller coaster year, the HealthTech Activator (HTA) is excited to announce several new, upcoming events across reimbursement, regulatory, and market validation topics.

Check out more info and links to the events, along with other news and resources, below!

We’d also love to hear about your needs: please complete this short survey (thank you to those who completed it last month) to tell us more about how we can help to build further resources for our community (approximately 3 mins).

________________________________________________________________________________________________________________________________________________________________________

HTA Events

HTA + Caduceus Medical Devlopment

Healthtech Regulatory Intelligence Interactive Tutorial (Online)

4 November

This interactive tutorial, facilitated by Tara Creaven-Capasso of Caduceus Medical Development, will give you tools and resources to make keeping up with regulatory changes and standards easier and more efficient.

Read more and register here
.

placeholder2

US Medical Device Reimbursement Interactive Tutorial (Online)

9 November

Join us for a US medical device reimbursement interactive tutorial with health economics and reimbursement specialist Jay Stracke. This will also include a discussion about the challenges for Software as a Medical Device (SaMD) products and will close with a Q&A.

Read more and register here.

HTA_Apagie

Putting Customers at the Heart of Healthtech (In-person workshop)

16-17 November, Auckland

We’re pleased to announce the HTA's newly developed in-person market validation workshops, the first of these will be: Putting customers at the heart of healthtech - clarifying who your customer is and developing your market entry approach.

The workshop is aimed at early stage healthtech companies, or companies that would like to have a fresh look at their customers, market and how they have validated it to date.

Read more and register here.

544624_MasterSeerPharmaLogowhitebackground_220819114859 (1)

Quality Management System eLearning (Online)

Ongoing

The Quality Management System Primer is a wholly online, self-paced course providing an overview of quality management systems, their benefits and what you need to consider before implementation. It is provided by SeerPharma and there is no cost to you for this programme.

Read more and register here.

_______________________________________________________________________________

HTA News

placeholder3

Finding Data to Validate Your Healthtech Market

HTA Team

Although the focus for healthtech companies is often on the clinical or economic data required to support claims and regulatory compliance, more foundational data about customer-value is also required to validate a target market. It’s also key to securing investment and partnerships. This month’s blog discusses market research and how the HTA can help.

Read more here.

________________________________________________________________________________________________________________________________________________________________________

Community Insights 

BioOra Launches:

High-tech 'cocoons' at Malaghan Institute aim to speed up cancer therapy trials

  • The Malaghan Institute and Bridgewest Ventures NZ launch BioOra, a company aiming to scale-up CAR T-cell therapy through novel automation technology.

Volpara’s Lung Expansion: 

Volpara signs second lung screening partnership (NBR-Paid)

  • Volpara continues its move into the lung cancer screening market with another partnership alongside ramping up its Volpara Lung platform build.

HeartLab Raises for US:

New Zealand startup HeartLab raises $2.45M to bring heart scanning software to the US

  • HeartLab’s echocardiogram platform solution, Pulse, continues to gain momentum with its latest raise. HeartLab is expecting FDA approval for Pulse in early 2022.

CLN5 Gene Therapy:

Gene therapy receives US FDA approval for in-human clinical trial

  • A team of Lincoln University researchers have received IND authorisation from the FDA for a therapy that delivers a functional CLN5 gene via a viral vector.

MedTech Bites:

August/September edition

  • The CMDT are co-developers of the HTA with Callaghan Innovation, and their MedTech Bites newsletter delivers interesting articles from across NZ healthtech.
Download
Download PDF
Download
Read on External Site